Summers K E, Goff L K, Wilson A G, Gupta R K, Lister T A, Fitzgibbon J
Imperial Cancer Research Fund Medical Oncology Unit, St Bartholomew's Hospital Medical College, London, United Kingdom.
J Clin Oncol. 2001 Jan 15;19(2):420-4. doi: 10.1200/JCO.2001.19.2.420.
To determine the incidence and frequency of the Bcl-2/IgH rearrangement in the peripheral blood of normal individuals to define the potential complication this may pose for the molecular monitoring of disease in patients with follicular lymphoma (FL).
The incidence and frequency of the major breakpoint cluster region rearrangement in DNA extracted from peripheral blood or lymphoblastoid cell lines from 481 normal individuals was determined using a TaqMan real-time polymerase chain reaction assay (PE Applied Biosystems, Foster City, CA).
Twenty three percent of samples were positive for the Bcl-2/IgH rearrangement, with approximately 3% of these at levels of more than 1 in 10(4) cells.
The presence of circulating Bcl-2/IgH+ cells, other than those derived from the malignant clone, could confound the detection and quantitation of minimal residual disease in patients with FL, particularly at low levels of tumor burden.
确定正常个体外周血中Bcl-2/IgH重排的发生率和频率,以明确其可能给滤泡性淋巴瘤(FL)患者疾病的分子监测带来的潜在并发症。
采用TaqMan实时聚合酶链反应检测法(PE应用生物系统公司,加利福尼亚州福斯特城),测定从481名正常个体的外周血或淋巴母细胞系中提取的DNA中主要断裂点簇区域重排的发生率和频率。
23%的样本Bcl-2/IgH重排呈阳性,其中约3%的样本细胞水平超过1/10⁴。
除源自恶性克隆的细胞外,循环中Bcl-2/IgH⁺细胞的存在可能会混淆FL患者微小残留病的检测和定量,尤其是在肿瘤负荷较低的情况下。